Donor T cells play a pivotal role in graft-versus-tumor (GVT) activity and graft-versus-host disease (GVHD) after HSCT. Although alloantigens are omnipresent in the recipient, GVHD is limited to a few organs (liver, intestines, and skin), and this selectivity is poorly understood.